{"id":23114,"date":"2025-01-26T10:57:56","date_gmt":"2025-01-26T02:57:56","guid":{"rendered":"https:\/\/flcube.com\/?p=23114"},"modified":"2025-01-26T10:58:01","modified_gmt":"2025-01-26T02:58:01","slug":"china-medical-system-partners-with-mabgeek-for-innovative-drug-mg-k10","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=23114","title":{"rendered":"China Medical System Partners with MabGeek for Innovative Drug MG-K10"},"content":{"rendered":"\n

China Medical System Holdings (CMS; HKG: 0867<\/a>) has announced a new license agreement with MabGeek Biotechnology Co., Ltd., a fellow Chinese biotech firm, for the latter’s Category 1 drug MG-K10. This marks CMS’s second major licensing deal in less than a month. Financial details of the agreement were not disclosed. Under the terms, CMS will obtain co-development and exclusive commercialization rights for MG-K10 in mainland China, Hong Kong, Macau, Taiwan, and Singapore. MabGeek will collaborate on commercial activities and will be responsible for selling and supplying the product.<\/p>\n\n\n\n

MG-K10: A Promising Anti-IL-4R\u03b1 Antibody<\/strong>
MG-K10 is an anti-IL-4R\u03b1 antibody that inhibits both IL-4 and IL-13 signaling pathways. It is designed to be a best-in-class drug with a monthly administration schedule, offering a favorable efficacy and safety profile. The initial indication for MG-K10 is atopic dermatitis (AD), a chronic inflammatory skin condition with significant unmet medical needs. The drug’s potential to provide long-term symptom control with less frequent dosing makes it an attractive candidate for patients and healthcare providers alike.<\/p>\n\n\n\n

Strategic Partnership for Regional Expansion<\/strong>
This partnership between CMS and MabGeek underscores the growing trend of collaboration within China’s biotech sector. CMS’s strong commercial presence in Greater China and Singapore will be instrumental in accelerating the development and market penetration of MG-K10. Meanwhile, MabGeek’s expertise in biotechnology research and development will ensure the drug’s scientific advancement. Together, the two companies aim to bring innovative treatment options to patients suffering from atopic dermatitis and other potential indications in the future.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China Medical System Holdings (CMS; HKG: 0867) has announced a new license agreement with MabGeek…<\/p>\n","protected":false},"author":1,"featured_media":23118,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,93,11],"tags":[30,325,844,3310],"class_list":["post-23114","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-digital","category-drug","tag-biotech","tag-china-medical-system","tag-hkg-0867","tag-mabgeek-biotechnology"],"yoast_head":"\nChina Medical System Partners with MabGeek for Innovative Drug MG-K10 - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China Medical System Holdings (CMS; HKG: 0867) has announced a new license agreement with MabGeek Biotechnology Co., Ltd., a fellow Chinese biotech firm, for the latter's Category 1 drug MG-K10. This marks CMS's second major licensing deal in less than a month. Financial details of the agreement were not disclosed. Under the terms, CMS will obtain co-development and exclusive commercialization rights for MG-K10 in mainland China, Hong Kong, Macau, Taiwan, and Singapore. MabGeek will collaborate on commercial activities and will be responsible for selling and supplying the product.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=23114\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"China Medical System Partners with MabGeek for Innovative Drug MG-K10\" \/>\n<meta property=\"og:description\" content=\"China Medical System Holdings (CMS; HKG: 0867) has announced a new license agreement with MabGeek Biotechnology Co., Ltd., a fellow Chinese biotech firm, for the latter's Category 1 drug MG-K10. This marks CMS's second major licensing deal in less than a month. Financial details of the agreement were not disclosed. Under the terms, CMS will obtain co-development and exclusive commercialization rights for MG-K10 in mainland China, Hong Kong, Macau, Taiwan, and Singapore. MabGeek will collaborate on commercial activities and will be responsible for selling and supplying the product.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=23114\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-26T02:57:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-26T02:58:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2601-png.avif\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23114#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23114\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"China Medical System Partners with MabGeek for Innovative Drug MG-K10\",\"datePublished\":\"2025-01-26T02:57:56+00:00\",\"dateModified\":\"2025-01-26T02:58:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23114\"},\"wordCount\":268,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23114#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/2601-png.avif\",\"keywords\":[\"Biotech\",\"China Medical System\",\"HKG: 0867\",\"MabGeek Biotech\"],\"articleSection\":[\"Company\",\"Digital\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23114#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23114\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=23114\",\"name\":\"China Medical System Partners with MabGeek for Innovative Drug MG-K10 - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23114#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23114#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/2601-png.avif\",\"datePublished\":\"2025-01-26T02:57:56+00:00\",\"dateModified\":\"2025-01-26T02:58:01+00:00\",\"description\":\"China Medical System Holdings (CMS; HKG: 0867) has announced a new license agreement with MabGeek Biotechnology Co., Ltd., a fellow Chinese biotech firm, for the latter's Category 1 drug MG-K10. This marks CMS's second major licensing deal in less than a month. Financial details of the agreement were not disclosed. Under the terms, CMS will obtain co-development and exclusive commercialization rights for MG-K10 in mainland China, Hong Kong, Macau, Taiwan, and Singapore. MabGeek will collaborate on commercial activities and will be responsible for selling and supplying the product.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23114#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23114\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23114#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/2601-png.avif\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/2601-png.avif\",\"width\":1080,\"height\":720,\"caption\":\"China Medical System Partners with MabGeek for Innovative Drug MG-K10\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23114#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"China Medical System Partners with MabGeek for Innovative Drug MG-K10\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"China Medical System Partners with MabGeek for Innovative Drug MG-K10 - Insight, China's Pharmaceutical Industry","description":"China Medical System Holdings (CMS; HKG: 0867) has announced a new license agreement with MabGeek Biotechnology Co., Ltd., a fellow Chinese biotech firm, for the latter's Category 1 drug MG-K10. This marks CMS's second major licensing deal in less than a month. Financial details of the agreement were not disclosed. Under the terms, CMS will obtain co-development and exclusive commercialization rights for MG-K10 in mainland China, Hong Kong, Macau, Taiwan, and Singapore. MabGeek will collaborate on commercial activities and will be responsible for selling and supplying the product.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=23114","og_locale":"en_US","og_type":"article","og_title":"China Medical System Partners with MabGeek for Innovative Drug MG-K10","og_description":"China Medical System Holdings (CMS; HKG: 0867) has announced a new license agreement with MabGeek Biotechnology Co., Ltd., a fellow Chinese biotech firm, for the latter's Category 1 drug MG-K10. This marks CMS's second major licensing deal in less than a month. Financial details of the agreement were not disclosed. Under the terms, CMS will obtain co-development and exclusive commercialization rights for MG-K10 in mainland China, Hong Kong, Macau, Taiwan, and Singapore. MabGeek will collaborate on commercial activities and will be responsible for selling and supplying the product.","og_url":"https:\/\/flcube.com\/?p=23114","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-01-26T02:57:56+00:00","article_modified_time":"2025-01-26T02:58:01+00:00","og_image":[{"width":1080,"height":720,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2601-png.avif","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=23114#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=23114"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"China Medical System Partners with MabGeek for Innovative Drug MG-K10","datePublished":"2025-01-26T02:57:56+00:00","dateModified":"2025-01-26T02:58:01+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=23114"},"wordCount":268,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=23114#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2601-png.avif","keywords":["Biotech","China Medical System","HKG: 0867","MabGeek Biotech"],"articleSection":["Company","Digital","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=23114#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=23114","url":"https:\/\/flcube.com\/?p=23114","name":"China Medical System Partners with MabGeek for Innovative Drug MG-K10 - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=23114#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=23114#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2601-png.avif","datePublished":"2025-01-26T02:57:56+00:00","dateModified":"2025-01-26T02:58:01+00:00","description":"China Medical System Holdings (CMS; HKG: 0867) has announced a new license agreement with MabGeek Biotechnology Co., Ltd., a fellow Chinese biotech firm, for the latter's Category 1 drug MG-K10. This marks CMS's second major licensing deal in less than a month. Financial details of the agreement were not disclosed. Under the terms, CMS will obtain co-development and exclusive commercialization rights for MG-K10 in mainland China, Hong Kong, Macau, Taiwan, and Singapore. MabGeek will collaborate on commercial activities and will be responsible for selling and supplying the product.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=23114#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=23114"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=23114#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2601-png.avif","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2601-png.avif","width":1080,"height":720,"caption":"China Medical System Partners with MabGeek for Innovative Drug MG-K10"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=23114#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"China Medical System Partners with MabGeek for Innovative Drug MG-K10"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2601-png.avif","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23114","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=23114"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23114\/revisions"}],"predecessor-version":[{"id":23117,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23114\/revisions\/23117"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/23118"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=23114"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=23114"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=23114"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}